NIH R01 · 2024
Oral anticancer medications (OAM) are becoming standard of care for growing numbers of patients. Multiple myeloma (MM), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL) are hematologic malignancies for which costly, long-term OAMs are a life-extending therapy. However, OAM nonadherence (i.e., delaying, not starting, taking more/less than prescribed, or stopping use) is a critical understudied issue that can dramatically affect cancer outcomes. The reasons for poor adherence, the characteristics of those at risk for poor adherence, and the effects of poor adherence on health outcomes are poorly understood, particularly in those with hematologic malignancies. Multi-level…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.